Lucid Diagnostics Announces Advances in Billing & Coding for EsoGuard

What Happened

Lucid Diagnostics, Inc. (LUCD) announced on September 22, 2026 (via an 8‑K and attached press release) that it has made advances in multiple payment, billing and coding pathways for its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. The disclosure follows three public meetings held the prior week and was furnished under Regulation FD; the company attached the press release as Exhibit 99.1 to the filing.

Key Details

• Filing date: September 22, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Subject: advances in payment, billing and coding pathways for EsoGuard® and EsoCheck®.
• Context: announcement followed three public meetings held the week before the filing.
• Exhibit: press release attached as Exhibit 99.1 (and Inline XBRL cover page filed as Exhibit 104).

Why It Matters

Clearer payment, billing and coding pathways are important early steps toward getting diagnostic tests reimbursed and easier to bill — which can reduce administrative barriers and support clinical adoption. For investors, this update is a non‑financial operational disclosure signaling progress on commercialization and reimbursement efforts; the 8‑K does not include revenue or financial results.